Test, Track, Treat Using Wearable Sensors for Management of Parkinson's Disease: 12‑month Prospective Observational United Arab Emirates Study Using Parkinson's Kinetograph (EmPark-PKG Study)

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2024 Dec 28

PMID 39730960

Authors

Vinod Metta

Mubasher A Qamar

Karolina Poplawska-Domaszewicz

Huzaifa Ibrahim

Hasna Hussain

Afsal Nalarakettil

Gloria Tanjung

K Ray Chaudhuri

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms that necessitate ongoing clinical evaluation and medication adjustments. Home-based wearable sensor monitoring offers a detailed and continuous record of patient symptoms, potentially enhancing disease management. The EmPark-PKG study aims to evaluate the effectiveness of the Parkinson's KinetoGraph (PKG), a wearable sensor device, in monitoring and tracking the progression of motor symptoms over 12 months in Emirati and non-Emirati PD patients. Fifty PD patients (32% Emirati, 68% non-Emirati) were assessed at baseline and a 12-month follow-up. Clinical evaluations included levodopa equivalent daily dosage (LEDD) and motor and non-motor assessments. Concurrently, the PKG provided metrics such as bradykinesia score (BKS) and dyskinesia score (DKS). Statistical analyses were conducted to determine changes from baseline to six months, differences between Emirati and non-Emirati groups, and correlations between PKG metrics and clinical assessments. Significant reductions in LEDD and improvements in both motor and non-motor scores were observed from baseline to six months (p < 0.05). PKG-guided medication adjustments were associated with enhanced motor and non-motor outcomes (p < 0.05). Specifically, non-Emirati patients exhibited a significant reduction in LEDD (Z = - 2.010, p = 0.044), whereas Emirati patients did not (Z = - 0.468, p = 0.640). Both groups showed significant improvements in motor scale scores and motor complication scores. Spearman correlation analysis revealed strong relationships between PKG metrics and subjective clinical assessments (p < 0.001). The EmPark-PKG study demonstrates the potential benefits of remote PKG monitoring for personalised motor symptom management in PD. PKG supports a stepped care paradigm by enabling bespoke medication titration based on objective data, facilitating tailored and effective patient care.

References

Alokley A, Alhubail F, Al Omair A, Alturki R, Alhaddad R, Al Mousa A . Assessing the perception of Parkinson's disease in Al-Ahsa, Saudi Arabia among the visitors of a public campaign: before and after survey. Front Neurol. 2024; 15:1365339. PMC: 11021784. DOI: 10.3389/fneur.2024.1365339. View

Ba F, Obaid M, Wieler M, Camicioli R, Martin W . Parkinson Disease: The Relationship Between Non-motor Symptoms and Motor Phenotype. Can J Neurol Sci. 2016; 43(2):261-7. DOI: 10.1017/cjn.2015.328. View

Bach J, Ziegler U, Deuschl G, Dodel R, Doblhammer-Reiter G . Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord. 2011; 26(12):2286-90. DOI: 10.1002/mds.23878. View

Ben-Joseph A, Marshall C, Lees A, Noyce A . Ethnic Variation in the Manifestation of Parkinson's Disease: A Narrative Review. J Parkinsons Dis. 2019; 10(1):31-45. PMC: 7029316. DOI: 10.3233/JPD-191763. View

Bhidayasiri R, Kalia L, Bloem B . Tackling Parkinson's Disease as a Global Challenge. J Parkinsons Dis. 2023; 13(8):1277-1280. PMC: 10741319. DOI: 10.3233/JPD-239005. View

Burn D, Rowan E, Minett T, Sanders J, Myint P, Richardson J . Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord. 2003; 18(8):884-9. DOI: 10.1002/mds.10455. View

Caballol N, Bayes A, Prats A, Martin-Baranera M, Quispe P . Feasibility of a wearable inertial sensor to assess motor complications and treatment in Parkinson's disease. PLoS One. 2023; 18(2):e0279910. PMC: 9894418. DOI: 10.1371/journal.pone.0279910. View

Chaudhuri K, Hu M, Brooks D . Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. Mov Disord. 2000; 15(1):18-23. DOI: 10.1002/1531-8257(200001)15:1<18::aid-mds1005>3.0.co;2-z. View

Chaudhuri K, Martinez-Martin P, Schapira A, Stocchi F, Sethi K, Odin P . International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006; 21(7):916-23. DOI: 10.1002/mds.20844. View

10.

Chaudhuri K, Titova N, Qamar M, Murasan I, Falup-Pecurariu C . The Dashboard Vitals of Parkinson's: Not to Be Missed Yet an Unmet Need. J Pers Med. 2022; 12(12). PMC: 9780936. DOI: 10.3390/jpm12121994. View

11.

Dautzenberg G, Lijmer J, Beekman A . Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry: Determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls. Int J Geriatr Psychiatry. 2019; 35(3):261-269. PMC: 7028034. DOI: 10.1002/gps.5227. View

12.

Djaldetti R, Hassin-Baer S, Farrer M, Vilarino-Guell C, Ross O, Kolianov V . Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. J Neural Transm (Vienna). 2008; 115(9):1279-84. DOI: 10.1007/s00702-008-0074-z. View

13.

El Masri J, Dankar R, El Masri D, Chanbour H, El Hage S, Salameh P . The Arab Countries' Contribution to the Research of Neurodegenerative Disorders. Cureus. 2021; 13(8):e17589. PMC: 8483433. DOI: 10.7759/cureus.17589. View

14.

Giladi N, Tal J, Azulay T, Rascol O, Brooks D, Melamed E . Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord. 2009; 24(5):655-61. DOI: 10.1002/mds.21745. View

15.

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

16.

Joshi R, Bronstein J, Keener A, Alcazar J, Yang D, Joshi M . PKG Movement Recording System Use Shows Promise in Routine Clinical Care of Patients With Parkinson's Disease. Front Neurol. 2019; 10:1027. PMC: 6779790. DOI: 10.3389/fneur.2019.01027. View

17.

Khalil H, Chahine L, Siddiqui J, Aldaajani Z, Bajwa J . Parkinson's disease in the MENASA countries. Lancet Neurol. 2020; 19(4):293-294. DOI: 10.1016/S1474-4422(20)30026-0. View

18.

Kolicheski A, Turcano P, Tamvaka N, McLean P, Springer W, Savica R . Early-Onset Parkinson's Disease: Creating the Right Environment for a Genetic Disorder. J Parkinsons Dis. 2022; 12(8):2353-2367. PMC: 9837689. DOI: 10.3233/JPD-223380. View

19.

Lewis S, Foltynie T, Blackwell A, Robbins T, Owen A, Barker R . Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005; 76(3):343-8. PMC: 1739569. DOI: 10.1136/jnnp.2003.033530. View

20.

McGregor S, Churchward P, Soja K, ODriscoll D, Braybrook M, Khodakarami H . The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson's disease. NPJ Parkinsons Dis. 2018; 4:1. PMC: 5762674. DOI: 10.1038/s41531-017-0038-9. View